EIGR - Eiger BioPharmaceuticals Inc Stock Price, Fair Value and News

$1.73

Market Closed

EIGR Stock Valuation Analysis

Valuation

Max Portfolio %

EIGR Price Action

EIGR RSI Chart

EIGR Stock Valuation Analysis

Valuation

Max Portfolio %

EIGR Valuation

EIGR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EIGR Fundamentals

EIGR Revenue

EIGR Earnings

EIGR Profitability

EIGR Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	15.5M	14.6M	14.4M
2022	11.2M	13.2M	14.1M	13.5M
2021	0	0	0	12.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

CEO	Dr. David Apelian M.B.A., M.D., MBA, Ph.D.
WEBSITE	eigerbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	56